A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.
Adam Zhang Yu
Advertisement
Founder & CEO, Collabrium Partners
Articles by Adam Zhang Yu
A growing number of domestic drug developers are setting their sights on overseas markets.
Licensing deals, strategy, and COVID among factors to consider for companies entering Chinese pharma M&A.
Advertisement
Latest Updated Articles
Exploring Biopharma's Dealmaking Terrain, Roadmap in ChinaPublished: January 27th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
GCC Emerges as a New Strategic Anchor for Global Venture Capital
3
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
4
Pharmaceutical Executive Presents: Most Favored Nation Order - How Trump Is Disrupting Pharma
5
